A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

A Phase 1，Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-421286 in Subjects With Advanced Solid Tumors

Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors.

Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.

Inclusion Criteria:

• Pathologically documented, locally-advanced or metastatic malignancy
• Standard treatment is not available or patient declines
• Adequate organ function

Exclusion Criteria:

• Active brain metastases from non-brain tumors.
• Gastrointestinal (GI) tract disease causing the inability to take oral medication.
• Other protocol specified criteria